These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 35359967)
1. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG Front Immunol; 2022; 13():840126. PubMed ID: 35359967 [TBL] [Abstract][Full Text] [Related]
2. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report. Nyström K; Hjorth M; Fust R; Nilsdotter-Augustinsson Å; Larsson M; Niward K; Nyström S BMC Infect Dis; 2022 Apr; 22(1):362. PubMed ID: 35410137 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424 [TBL] [Abstract][Full Text] [Related]
4. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. Steiner S; Schwarz T; Corman VM; Sotzny F; Bauer S; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG Front Immunol; 2021; 12():687449. PubMed ID: 34322120 [TBL] [Abstract][Full Text] [Related]
5. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. Herman JD; Wang C; Loos C; Yoon H; Rivera J; Eugenia Dieterle M; Haslwanter D; Jangra RK; Bortz RH; Bar KJ; Julg B; Chandran K; Lauffenburger D; Pirofski LA; Alter G Nat Commun; 2021 Nov; 12(1):6853. PubMed ID: 34824251 [TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105 [TBL] [Abstract][Full Text] [Related]
7. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. Kinoshita H; Durkee-Shock J; Jensen-Wachspress M; Kankate VV; Lang H; Lazarski CA; Keswani A; Webber KC; Montgomery-Recht K; Walkiewicz M; Notarangelo LD; Burbelo PD; Fuss I; Cohen JI; Bollard CM; Keller MD J Clin Immunol; 2021 Aug; 41(6):1146-1153. PubMed ID: 33983545 [TBL] [Abstract][Full Text] [Related]
8. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies. Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S Front Immunol; 2023; 14():1275892. PubMed ID: 37901210 [TBL] [Abstract][Full Text] [Related]
9. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Orologas-Stavrou N; Politou M; Rousakis P; Kostopoulos IV; Ntanasis-Stathopoulos I; Jahaj E; Tsiligkeridou E; Gavriatopoulou M; Kastritis E; Kotanidou A; Dimopoulos MA; Tsitsilonis OE; Terpos E Viruses; 2020 Dec; 13(1):. PubMed ID: 33375675 [TBL] [Abstract][Full Text] [Related]
10. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W Front Immunol; 2021; 12():684014. PubMed ID: 34194438 [TBL] [Abstract][Full Text] [Related]
11. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency. Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946 [TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584 [TBL] [Abstract][Full Text] [Related]